Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Pateclizumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Pateclizumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Pateclizumab. |
| Estrone | Estrone may increase the thrombogenic activities of Pateclizumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Pateclizumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Pateclizumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Pateclizumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Pateclizumab. |
| Estriol | Estriol may increase the thrombogenic activities of Pateclizumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Pateclizumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Pateclizumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Pateclizumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Pateclizumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Pateclizumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Pateclizumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Pateclizumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Pateclizumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Pateclizumab. |
| Equol | Equol may increase the thrombogenic activities of Pateclizumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Pateclizumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Pateclizumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Pateclizumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Pateclizumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Pateclizumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Pateclizumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Pateclizumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Pateclizumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Pateclizumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Pateclizumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Pateclizumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Pateclizumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pateclizumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Pateclizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Pateclizumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Pateclizumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pateclizumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pateclizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Pateclizumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pateclizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Pateclizumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Pateclizumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Pateclizumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pateclizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pateclizumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Pateclizumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pateclizumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pateclizumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Pateclizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pateclizumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Pateclizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Pateclizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Pateclizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pateclizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pateclizumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Pateclizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Pateclizumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Pateclizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Pateclizumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Pateclizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Pateclizumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Pateclizumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Pateclizumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Pateclizumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Pateclizumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Pateclizumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Pateclizumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Pateclizumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Pateclizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Pateclizumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Pateclizumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Pateclizumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Pateclizumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Pateclizumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Pateclizumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Pateclizumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Pateclizumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Pateclizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Pateclizumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Pateclizumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Pateclizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Pateclizumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Pateclizumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Pateclizumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Pateclizumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Pateclizumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Pateclizumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Pateclizumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Pateclizumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Pateclizumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Pateclizumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Pateclizumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Pateclizumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Pateclizumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Pateclizumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Pateclizumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Pateclizumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Pateclizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Pateclizumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Pateclizumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Pateclizumab. |